Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05570630 · ClinicalTrials.gov registry record · NA
VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 6,911
- Enrollment target
NCT05570630: Completed NA study, sponsored by University of Rochester.
NCT05570630 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 6,911 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (393% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05570630, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 6,911 participants
- Enrollment target
Study Summary
COVID-19 infection during pregnancy is associated with increased risk of pre-eclampsia, preterm birth and stillbirth. Pregnant people with COVID-19 have a higher rate of ICU admission and intubation than those who are not pregnant. COVID-19 vaccine is recommended before pregnancy and during pregnancy to decrease these risks. Despite the benefits of COVID-19 vaccination, only 71% of pregnant women were vaccinated for COVID-19 as of June 2022 (most prior to pregnancy), with a much lower rate of 58% among non-Hispanic Black women. An effective intervention is needed to improve COVID vaccination rates for pregnant people overall. In this study, the investigators will perform a randomized controlled trial aimed at practice change in obstetricians' offices, with an overall goal of increasing maternal COVID-19 vaccination rates.
Primary Outcome
Average rate of COVID-19 vaccination will be compared between intervention and control arms, for vaccine eligible patients at participating OB/GYN practice sites. Vaccination status will be obtained from patient electronic health records.
Interventions
- OTHER Standard of Care
- BEHAVIORAL VAX-MOM COVID-19 Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,911 participants |
| Start Date | 2022-10-21 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
What the finished NCT05570630 record still lists
NCT05570630 is an interventional study that assigns participants to a tested intervention. Its 6,911 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (393% higher).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT05570630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05570630 about?
NCT05570630 is a clinical study titled "VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination". COVID-19 infection during pregnancy is associated with increased risk of pre-eclampsia, preterm birth and stillbirth. Pregnant people with COVID-19 have a higher rate of ICU admission and intubation than those who are not pregnant. COVID-19 vaccine is recommended before pregnancy and during pregnanc...
What is the current status of trial NCT05570630?
This trial is currently completed. It is a NA study. The enrollment target is 6,911 participants. The study started on 2022-10-21. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05570630?
The interventions under investigation include: Standard of Care (OTHER), VAX-MOM COVID-19 Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05570630?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05570630's enrollment target sits among peer trials
6,911 21st of 2000 higher than 1,980 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06234384 · 6,833 participants
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
- NCT04118660 · 7,000 participants
Thoracic Specimen Registry
- NCT07106879 · 7,000 participants
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI